Publications by authors named "Disebo Potloane"
Purpose Of Review: Women in Africa bear the burden of the HIV epidemic, which has been associated with the high prevalence of bacterial vaginosis (BV) in the region. However, little progress has been made in finding an effective cure for BV. Drawing on advances in microbiome-directed therapies for gastrointestinal disorders, similar live-biotherapeutic based approaches for BV treatment are being evaluated.
View Article and Find Full Text PDFLimited studies have been conducted on the safety and effectiveness of heterologous COVID-19 vaccine boosting in lower income settings, especially those with high-HIV prevalence., The Sisonke Heterologous mRNA-1273 boost after prime with Ad26.COV2.
View Article and Find Full Text PDFArticle Synopsis
- In sub-Saharan Africa, girls aged 15-19 represent 86% of HIV infections, underscoring the need to understand risk factors affecting them compared to adult women in South Africa.
- A study of 305 adolescent girls and 114 adult women in two South African provinces revealed that while adults reported higher risk sexual behaviors, adolescents had a higher prevalence of STIs (62.8% vs 34.0% in the Western Cape).
- Factors like earlier sexual debut and the use of intravaginal sexual enhancers among adolescents were significant, and behavioral risk factors such as the number of sexual partners and recent sexual activity were linked to STI presence in both age groups.
Background: There are gaps in uptake of, adherence to, and persistence in the use of preexposure prophylaxis for human immunodeficiency virus (HIV) prevention among cisgender women.
Methods: We conducted a phase 3, double-blind, randomized, controlled trial involving adolescent girls and young women in South Africa and Uganda. Participants were assigned in a 2:2:1 ratio to receive subcutaneous lenacapavir every 26 weeks, daily oral emtricitabine-tenofovir alafenamide (F/TAF), or daily oral emtricitabine-tenofovir disoproxil fumarate (F/TDF; active control); all participants also received the alternate subcutaneous or oral placebo.
Introduction: Women-controlled HIV prevention technologies that overcome adherence challenges of available daily oral pre-exposure prophylaxis and give women a choice of options are urgently needed. Broadly neutralising monoclonal antibodies (bnAbs) administered passively may offer a valuable non-antiretroviral biological intervention for HIV prevention. Animal and human studies have demonstrated that bnAbs which neutralise HIV can prevent infection.
View Article and Find Full Text PDF